Pfizer to pay $2.26B for cancer treatment developer Trillium
![<i></i><br/>](https://abc17news.b-cdn.net/abc17news.com/2021/06/kmiz-biz-and-tech.png)
By The Associated Press
Pfizer is spending more than $2 billion in cash to buy another drugmaker focused on potential cancer treatments. New York-based Pfizer says it will pay $18.50 for each share of Trillium Therapeutics Inc., or more than double the stock’s 60-day weighted average price. Trillium has no products on the market. Its potential treatments include biologics that aim to prime a patient’s immune system to detect and destroy cancer cells. Its two lead candidates are in early-stage testing and focus on hematology. That includes blood, bone marrow and lymph node cancers like leukemia or lymphoma.